Sign In
Buy NOVT
NOVT Earnings Calls
| Release date | Nov 03, 2025 |
| EPS estimate | $0.81 |
| EPS actual | $0.87 |
| EPS Surprise | 7.41% |
| Revenue estimate | 255.589M |
| Revenue actual | 247.836M |
| Revenue Surprise | -3.03% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.740 |
| EPS actual | $0.760 |
| EPS Surprise | 2.70% |
| Revenue estimate | 248.475M |
| Revenue actual | 241.049M |
| Revenue Surprise | -2.99% |
| Release date | May 06, 2025 |
| EPS estimate | $0.680 |
| EPS actual | $0.740 |
| EPS Surprise | 8.82% |
| Revenue estimate | 240.741M |
| Revenue actual | 233.366M |
| Revenue Surprise | -3.06% |
| Release date | Feb 25, 2025 |
| EPS estimate | $0.81 |
| EPS actual | $0.760 |
| EPS Surprise | -6.17% |
| Revenue estimate | 244.578M |
| Revenue actual | 238.06M |
| Revenue Surprise | -2.66% |
Last 4 Quarters for NOVT
Below you can see how NOVT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | $148.25 |
| EPS estimate | $0.81 |
| EPS actual | $0.760 |
| EPS surprise | -6.17% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $145.20 |
| Feb 20, 2025 | $142.80 |
| Feb 21, 2025 | $140.51 |
| Feb 24, 2025 | $138.30 |
| Feb 25, 2025 | $148.25 |
| Feb 26, 2025 | $149.30 |
| Feb 27, 2025 | $145.33 |
| Feb 28, 2025 | $144.64 |
| Mar 03, 2025 | $143.37 |
| 4 days before | 2.10% |
| 4 days after | -3.29% |
| On release day | 0.708% |
| Change in period | -1.26% |
| Release date | May 06, 2025 |
| Price on release | $117.69 |
| EPS estimate | $0.680 |
| EPS actual | $0.740 |
| EPS surprise | 8.82% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $118.86 |
| May 01, 2025 | $120.79 |
| May 02, 2025 | $121.98 |
| May 05, 2025 | $120.01 |
| May 06, 2025 | $117.69 |
| May 07, 2025 | $118.91 |
| May 08, 2025 | $121.91 |
| May 09, 2025 | $122.84 |
| May 12, 2025 | $131.68 |
| 4 days before | -0.98% |
| 4 days after | 11.89% |
| On release day | 1.04% |
| Change in period | 10.79% |
| Release date | Aug 05, 2025 |
| Price on release | $115.70 |
| EPS estimate | $0.740 |
| EPS actual | $0.760 |
| EPS surprise | 2.70% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $123.24 |
| Jul 31, 2025 | $123.02 |
| Aug 01, 2025 | $120.10 |
| Aug 04, 2025 | $124.01 |
| Aug 05, 2025 | $115.70 |
| Aug 06, 2025 | $113.74 |
| Aug 07, 2025 | $113.73 |
| Aug 08, 2025 | $115.67 |
| Aug 11, 2025 | $113.14 |
| 4 days before | -6.12% |
| 4 days after | -2.21% |
| On release day | -1.69% |
| Change in period | -8.20% |
| Release date | Nov 03, 2025 |
| Price on release | $135.86 |
| EPS estimate | $0.81 |
| EPS actual | $0.87 |
| EPS surprise | 7.41% |
| Date | Price |
|---|---|
| Oct 28, 2025 | $127.68 |
| Oct 29, 2025 | $128.61 |
| Oct 30, 2025 | $125.22 |
| Oct 31, 2025 | $127.01 |
| Nov 03, 2025 | $135.86 |
| Nov 04, 2025 | $129.33 |
| Nov 05, 2025 | $132.48 |
| Nov 06, 2025 | $107.26 |
| Nov 07, 2025 | $105.45 |
| 4 days before | 6.41% |
| 4 days after | -22.38% |
| On release day | -4.81% |
| Change in period | -17.41% |
NOVT Earnings Call Transcript Summary of Q3 2025
Novanta beat expectations in Q3 2025 with record revenue of $248M (reported +1%, organic -4%), stronger-than-expected margins (adjusted gross margin 46.5%, adjusted EBITDA margin ~23%), and adjusted EPS of $0.87. Key operational highlights: new product revenue jumped ~60% YoY, bookings grew 17% YoY (book-to-bill 1.03), and design-win activity accelerated (50% YTD). Management says momentum is broad-based across Advanced Surgery (strong double-digit growth and new insufflator wins), Robotics & Automation (design wins in warehouse automation and nascent humanoid opportunities), and improving Precision Manufacturing; Precision Medicine remains more volatile. Management expects to have turned the corner, guiding Q4 2025 revenue $253M–$257M (organic ~+3% YoY) and full-year 2025 revenue ~$975M–$979M. They forecast a return to positive organic growth in Q4 and a baseline of mid-single-digit organic growth for 2026, with long-term targets of mid- to high-single-digit organic growth driven by medical technologies, consumables and embedded software. Financial positioning: gross debt $457M (net leverage ~1.7x), opportunistic buybacks (additional $200M authorization), acquisitions remain a top capital allocation priority. Management is executing regionalized manufacturing and ERP initiatives, expects tariff impacts to be mitigated, and anticipates roughly +100 bps gross margin uplift from regional manufacturing over time. Cash conversion was weaker in Q3 due to timing (tax payments, restructuring and inventory build) but is expected to recover to >100% of net income over the full year.
